fbpx

Aarvik Therapeutics and ArriVent Biopharma Advance Novel Oncology Drug Candidate Through Strategic Collaboration and Modular Antibody Platform

Aarvik Therapeutics, a biotechnology company focused on engineering precision medicines for cancer therapy, has achieved a significant milestone in its collaboration with ArriVent BioPharma, Inc. The partnership, which was initiated on December 21, 2021, involves the development and commercialization of a novel oncology drug candidate using Aarvik’s proprietary modular antibody platform.

Under the terms of the agreement, Aarvik has been responsible for the discovery and preclinical development of the novel molecule, which combines multiple target mechanisms to enhance efficacy and safety. ArriVent, with its strong global development expertise, will lead the clinical development and commercialization of the drug candidate.

Aarvik has received an upfront payment, research funding, and an opt-in payment as part of the collaboration. The company is also eligible to receive contingent development and commercial milestones, plus royalties, which could total approximately $100 million.

The collaboration leverages Aarvik’s innovative modular platform, which enables the rapid creation of a pipeline of differentiated programs across a range of therapeutic targets. Jagath Reddy Junutula, Ph.D., Co-founder, President, and CEO of Aarvik Therapeutics, emphasized the importance of this partnership, stating, “This collaboration with ArriVent leverages their strong global development expertise, enabling us to expeditiously advance a novel cancer therapeutic into the clinic. We are excited to partner with ArriVent’s team, which brings a proven clinical track record in this space.”

Bing Yao, Ph.D., Chairman, Co-founder, and CEO of ArriVent Biopharma, highlighted the strategic nature of the partnership, saying, “Our main business focus at ArriVent is to identify and secure strategic partnerships with companies such as Aarvik who share a similar vision of advancing highly innovative molecules for difficult to treat diseases such as cancer.”

The collaboration has reached a critical milestone with ArriVent exercising its option to exclusively license the collaboration program. This decision underscores the potential of Aarvik’s modular antibody platform and the company’s ability to develop novel oncology therapies.

Aarvik Therapeutics combines unique, proprietary modular platforms with multiple target mechanisms to develop novel molecules with an improved therapeutic index for oncology targets. The company is backed by extensive scientific, research, development, and business expertise from its founders, team members, Scientific Advisory Board, and Board of Directors.

ArriVent BioPharma, Inc. is dedicated to accelerating the global development of innovative biopharmaceutical products. With a deep, global network of biotechs and big Pharma, ArriVent has access to unique and best-in-class drug candidates at various development stages, including those coming from China and other emerging biotech hubs.

The partnership between Aarvik Therapeutics and ArriVent BioPharma, Inc. aims to rapidly advance a highly novel therapy for patients to benefit globally. This collaboration is a testament to the power of strategic partnerships in advancing innovative therapies for difficult-to-treat diseases such as cancer.

Aarvik Therapeutics continues to pursue previously hard-to-treat indications through the power of its novel multi-targeting platforms. The company’s vision and passion are centered on creating transformational benefits for cancer patients. With this collaboration, Aarvik Therapeutics is well-positioned to deliver transformative therapeutics to patients in an accelerated timeframe.

The exercise of the option by ArriVent BioPharma, Inc. to exclusively license the collaboration program marks a significant step forward in the development of novel oncology therapies. This partnership highlights the potential of Aarvik’s modular antibody platform and the company’s commitment to advancing innovative therapies for cancer patients.


Get more clients for your agency – pitch your business to recently funded startups.

Company

© 2025 Fundraise Insider. All Rights Reserved.